Akèy › Dyabèt Tip 2 › Arizona › Tucson

Etid klinik pou Dyabèt Tip 2 nan Tucson, AZ

10 etid pou Dyabèt Tip 2 ap chèche patisipan nan sit nan ak bò kote Tucson (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Ap rekriteFaz 2

Pima Heart, Tucson
Eclipse Clinical Research, Tucson

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07783802

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Ap rekriteFaz 3

Arizona Clinical Trials, Tucson

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07064473

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

Ap rekriteVolontè an sante akeyi

Noble Clinical Research, Tucson

Laj 55 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06112418

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Ap rekriteFaz 3

Tucson Clinical Research Institute, Tucson

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07282600

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Ap rekriteFaz 3

Research Site, Tucson

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07784270

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Ap rekriteFaz 3

AURORA-2 Clinical Site, Tucson

Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743450

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Ap rekriteFaz 3

Arizona Clinical Trials, Tucson

Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351058

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Ap rekriteFaz 2

Arizona Clinical Trials - Broadway, Tucson

Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07296484

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Ap rekriteFaz 2

Pima Heart, Tucson

Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT07215559

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

Ap rekriteFaz 3

University of Arizona, Tucson

Laj 10 a 17 · Tout sèks · Mizajou Aug 7, 2026 · NCT06739122

Etid Dyabèt Tip 2 nan lòt vil

Lòt etid nan Tucson

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.